Phase II Study in Patients With Operable Breast Cancer
NCT00518583
Unknown
The study will evaluate the safety and efficacy of the combination PLD, paclitaxel, and trastuzumab in patients with operable breast cancer. Patients will be treated with the combination for 18 weeks, followed by surgery.
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
01/14/2010
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Breast Cancer
Register for Updates
TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium
NCT00077688
Completed
Phase 2B, multicenter study evaluating the safety and efficacy of weekly TOCOSOL Paclitaxel in taxane-naive patients receiving second line chemotherapy for metastatic or locally advanced, unresectable transitional cell carcinoma of the urothelium
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2009
Locations: Cleveland Clinic Foundation, Cleveland, Ohio
Conditions: Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Carcinoma, Transitional Cell
Register for Updates
Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer
NCT00251095
Terminated
The purpose of this study is to compare the objective response rates of patients randomized to receive either TOCOSOL(R) Paclitaxel or Taxol(R) (paclitaxel injection) administered every week to patients with metastatic breast cancer. The study hypothesis is that the objective response rate with TOCOSOL Paclitaxel given every week is non-inferior to that observed with Taxol given every week.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/02/2009
Locations: Hematology Oncology Consultants, Inc, Columbus, Ohio
Conditions: Breast Neoplasm
Register for Updates
Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)
NCT00087802
Completed
The purpose of this study is to compare combination treatment of gemcitabine + oxaliplatin (GEMOX) with carboplatin + paclitaxel (CP) to determine if there is a difference in response and safety between the two drug combinations for the treatment of advanced non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2009
Locations: Dayton Oncology & Hematology, P.A., Kettering, Ohio
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program
NCT00569751
Completed
The TAXUS ARRIVE 2 study is a multi-center safety and surveillance study designed to to compile safety surveillance and clinical outcomes data for the TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System in routine clinical practice and to identify low frequency TAXUS related clinical events.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/25/2008
Locations: Bethesda North Hospital, Cincinnati, Ohio +3 locations
Conditions: Cardiovascular Disease, de Novo Coronary Lesions
Register for Updates
Phase II CT-2103/Carboplatin in Ovarian Cancer
NCT00069901
Completed
The purpose of this study is to evaluate the safety and efficacy of CT-2103 (poly(L)glutamate-paclitaxel) in combination with carboplatin for the treatment of patients with Stage III or IV ovarian or primary peritoneal cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/18/2008
Locations: Gynecology, Oncology, and Pelvic Surgery Associates, Inc., Columbus, Ohio
Conditions: Ovarian Neoplasm
Register for Updates
Chemotherapy in Treating Patients With Metastatic Kidney Cancer
NCT00024388
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who have locally advanced, metastatic, or unresectable kidney cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2008
Locations: Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio
Conditions: Kidney Cancer
Register for Updates
Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer
NCT00025688
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if paclitaxel is more effective with or without carboplatin in treating stage IV breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel with or without carboplatin in treating women who have stage IV breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/23/2008
Locations: Clinical Hematology & Oncology Service, Inc., Akron, Ohio
Conditions: Breast Cancer
Register for Updates
Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus
NCT00003326
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with metastatic, recurrent, or unresectable cancer of the esophagus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2008
Locations: Akron City Hospital, Akron, Ohio
Conditions: Esophageal Cancer
Register for Updates
Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer
NCT00003327
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with recurrent or refractory head and neck cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2008
Locations: Akron City Hospital, Akron, Ohio +1 locations
Conditions: Head and Neck Cancer
Register for Updates